Perspective Therapeutics (NYSE:CATX) Given New $16.00 Price Target at Royal Bank of Canada

Perspective Therapeutics (NYSE:CATX) had its price objective decreased by Royal Bank of Canada from $25.00 to $16.00 in a research note released on Monday,Benzinga reports. Royal Bank of Canada currently has an outperform rating on the stock.

CATX has been the subject of a number of other reports. UBS Group began coverage on shares of Perspective Therapeutics in a research note on Thursday, October 24th. They issued a “buy” rating and a $20.00 price objective for the company. Oppenheimer cut their target price on shares of Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating for the company in a research report on Friday. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Perspective Therapeutics in a research report on Monday, September 9th. Bank of America cut Perspective Therapeutics from a “buy” rating to a “neutral” rating and cut their price objective for the stock from $24.00 to $5.00 in a research report on Monday. Finally, Wedbush reaffirmed an “outperform” rating and issued a $11.00 target price (down previously from $20.00) on shares of Perspective Therapeutics in a report on Thursday, November 21st. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $15.14.

Perspective Therapeutics Price Performance

Shares of NYSE:CATX opened at $3.69 on Monday. Perspective Therapeutics has a 1 year low of $2.28 and a 1 year high of $19.05. The stock has a fifty day simple moving average of $11.33.

Perspective Therapeutics (NYSE:CATX) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.21) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.21). Perspective Therapeutics had a negative return on equity of 27.40% and a negative net margin of 4,096.66%. The company had revenue of $0.37 million during the quarter. As a group, equities analysts anticipate that Perspective Therapeutics will post -0.86 EPS for the current year.

Institutional Trading of Perspective Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. Vanguard Group Inc. lifted its position in Perspective Therapeutics by 34.6% in the first quarter. Vanguard Group Inc. now owns 17,780,106 shares of the company’s stock worth $21,158,000 after purchasing an additional 4,566,356 shares during the period. Janus Henderson Group PLC acquired a new stake in shares of Perspective Therapeutics during the 1st quarter valued at about $15,511,000. Virtu Financial LLC bought a new stake in Perspective Therapeutics in the first quarter valued at about $138,000. Bank of New York Mellon Corp raised its position in Perspective Therapeutics by 214.0% in the second quarter. Bank of New York Mellon Corp now owns 137,268 shares of the company’s stock worth $1,369,000 after purchasing an additional 93,548 shares in the last quarter. Finally, Rhumbline Advisers bought a new position in Perspective Therapeutics during the second quarter worth about $630,000. 54.66% of the stock is currently owned by institutional investors.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.